TX2100

TX2100 is a VHH-Fc fusion antagonist antibody biotherapeutic developed by Tectonic Therapeutic for the treatment of hereditary hemorrhagic telangiectasia (HHT), the second most common genetic bleeding disorder. HHT is characterized by abnormal blood vessel formations (telangiectasias and arteriovenous malformations) that are prone to recurrent, severe bleeding. The disease results from loss-of-function mutations in the BMP9/10-Endoglin-ALK1-SMAD4 signaling pathway, leading to increased expression of angiogenic factors. TX2100 targets an undisclosed G protein-coupled receptor (GPCR), referred to as "GPCR3," which is upregulated in animal models of HHT and plays a key role in pathogenic angiogenesis. By antagonizing this GPCR, TX2100 aims to reduce abnormal blood vessel formation and associated bleeding episodes in HHT patients. Preclinical studies have shown efficacy in reducing arteriovenous malformation development and bleeding, with no significant toxicity observed at high doses in non-human primates[1][3][5].